Skip to main content
If you continue browsing this website, you agree to our policies:
  • Cookie Statement
  • Privacy Policy
  • Personal Data Protection Policy
Continue
x
  • Welcome to the Wits RHI eLearning Portal.
Font size: AAA
Wits RHI eLearning Portal
    ×

    Forgot your username or password?

    SearchCloseLog inClose

    IMPAACT 2036 MOP: Phase I/II Study of the Safety, Tolerability, Acceptability & Pharmacokinetics of Oral & Long-Acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to

    1. Home
    2. Courses
    3. Shandukani Research Centre
    4. Protocols and MOPs
    5. IMPAACT 2036
    6. Shan_IMPAACT2036_MOP_V3
    7. Summary
    IMPAACT 2036 MOP: Phase I/II Study of the Safety, Tolerability, Acceptability & Pharmacokinetics of Oral & Long-Acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to

    IMPAACT 2036 MOP: Phase I/II Study of the Safety, Tolerability, Acceptability & Pharmacokinetics of Oral & Long-Acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to

    Enter this course

    Blocks

    Skip Navigation

    Navigation

    • Home

      • My courses

      • Search

      • ForumSite announcements

      • My courses

      • Courses

        • Shandukani Research Centre

          • SUSARS

          • SOPs

          • Protocols and MOPs

            • RSV_IMPACT

            • IMPAACT 2036

              • IMPAACT_2036_Protocol_V3

              • IMPAACT_ MOPI_#4

              • Shan_IMPAACT2036_Lab Processing Chart_V3

              • Shan_IMPAACT2036_MOP_V5

              • Shan_IMPAACT2036_MOP_V4

              • IMPAACT_ eCRF_V2.0.0.2

              • Shan_IMPAACT2036_MOP_V3

              • IMPAACT_Protocol and MOP_V2.0_V3.0

              • IMPAACT_ LPC_V2.0

              • IMPAACT_ MOPI_#3

              • IMPAACT_ CM2

            • SHIELD

            • C1091009 (BEATRIX)

            • GS-US-200-6712

            • GS-US-621-6463

            • GS-US-380-6684

            • MK066

            • PATH300269_Protocol_V1

            • GSK PATH 300269_ PM_V1

            • RTMC4002_IB_Ed19

            • RRS

            • P2CT

            • MVX

            • SIV15

            • PA6

            • OLE

            • PGSA

            • SIVS

          • General

          • Archive

        • Gophelega Project

        • General

        • Implementation Science

        • Wits RHI Research Team

    • Should you have any navigation queries, please email wrhitraining@academicadvance.co.za.

    Academic Advance 2020. All rights reserved.

    Hide sidebars